Abstract
Pharmacokinetics of an original compound GB-115 (N-phenylhexanoylglycyltryptophan) synthesized on the basis of the structure of endogenous tetrapeptide cholecystokinin-4 was studied by means of high-performance liquid chromatography. Pharmacokinetic parameters were calculated after intravenous and peroral administration of GB-115. Our results indicate that this dipeptide is resistant to peptidases. The absolute bioavailability of GB-115 is 4.65%.
Similar content being viewed by others
References
A. A. Agafonov and V. K. Piotrovskii, Khim. Farm. Zh., No. 10, 16–19 (1991).
T. A. Gudasheva, E. P. Kir’yanova, L. G. Kolik, et al., Bioorgan. Khimiya, 33, No. 2, 1–8 (2007).
J. N. Crawley and R. L. Corwin, Peptides, 15, No. 4, 731–755 (1994).
R. Herranz, Med. Res. Rev., 23, No. 5, 559–605 (2003).
F. Noble and B. P. Rogues, Prog. Neurobiol., 58, No. 4, 349–379 (1999).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 144, No. 9, pp. 285–287, September, 2007
Rights and permissions
About this article
Cite this article
Boyko, S.S., Kolyvanov, G.B., Zherdev, V.P. et al. Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115. Bull Exp Biol Med 144, 312–313 (2007). https://doi.org/10.1007/s10517-007-0319-0
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10517-007-0319-0